Literature DB >> 15562003

RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.

Tadashi Mori1, Akihiro Oguro, Takashi Ohtsu, Yoshikazu Nakamura.   

Abstract

The receptor activator of NF-kappaB (RANK) is a member of the tumor necrosis factor (TNF) receptor family and acts to cause osteoclastgenesis through the interaction with its ligand, RANKL. We isolated RNA aptamers with high affinity to human RANK by SELEX. Sequence and mutational analysis revealed that the selected RNAs form a G-quartet conformation that is crucial for binding to RANK. When the aptamer binding to RANK was challenged by RANKL, there was no competition between the aptamer and RANKL. Instead, the formation of a ternary complex, aptamer-RANK-RANKL, was detected by a spin down assay and by BIAcore surface plasmon resonance analysis. Moreover, the selected aptamer efficiently bound to other TNF receptor family proteins, such as TRAIL-R2, CD30, NGFR as well as osteoprotegerin, a decoy receptor for RANK. These results suggest that the selected aptamer recognizes not the ligand-binding site, but rather a common structure conserved in the TNF receptor family proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562003      PMCID: PMC534629          DOI: 10.1093/nar/gkh949

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  41 in total

Review 1.  Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.

Authors:  P C Taylor; R O Williams; R N Maini
Journal:  Curr Dir Autoimmun       Date:  2000

Review 2.  The molecular architecture of the TNF superfamily.

Authors:  Jean-Luc Bodmer; Pascal Schneider; Jürg Tschopp
Journal:  Trends Biochem Sci       Date:  2002-01       Impact factor: 13.807

3.  Generation of RNA aptamers to the G-protein-coupled receptor for neurotensin, NTS-1.

Authors:  Dion A Daniels; Awinder K Sohal; Stephen Rees; Reinhard Grisshammer
Journal:  Anal Biochem       Date:  2002-06-15       Impact factor: 3.365

4.  Interaction of ribosome recycling factor and elongation factor EF-G with E. coli ribosomes studied by the surface plasmon resonance technique.

Authors:  T Ishino; K Atarashi; S Uchiyama; T Yamami; Y Saihara; T Yoshida; H Hara; K Yokose; Y Kobayashi; Y Nakamura
Journal:  Genes Cells       Date:  2000-12       Impact factor: 1.891

Review 5.  RNA targets of the fragile X protein.

Authors:  M D Kaytor; H T Orr
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

Review 6.  The role of chemokines and chemokine receptors in mucosal inflammation.

Authors:  K A Papadakis; S R Targan
Journal:  Inflamm Bowel Dis       Date:  2000-11       Impact factor: 5.325

Review 7.  Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.

Authors:  L C Hofbauer; A Neubauer; A E Heufelder
Journal:  Cancer       Date:  2001-08-01       Impact factor: 6.860

8.  Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.

Authors:  J Lam; C A Nelson; F P Ross; S L Teitelbaum; D H Fremont
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 9.  A family of ligands for the TNF receptor superfamily.

Authors:  D Cosman
Journal:  Stem Cells       Date:  1994-09       Impact factor: 6.277

Review 10.  The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.

Authors:  E M Gravallese; D L Galson; S R Goldring; P E Auron
Journal:  Arthritis Res       Date:  2000-11-02
View more
  27 in total

1.  A mathematical analysis of SELEX.

Authors:  Howard A Levine; Marit Nilsen-Hamilton
Journal:  Comput Biol Chem       Date:  2007-01-10       Impact factor: 2.877

2.  Hybridization of complementary and homologous peptide nucleic acid oligomers to a guanine quadruplex-forming RNA.

Authors:  Violeta L Marin; Bruce A Armitage
Journal:  Biochemistry       Date:  2006-02-14       Impact factor: 3.162

Review 3.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

Review 4.  Cell-specific aptamers for targeted therapies.

Authors:  Laura Cerchia; Paloma H Giangrande; James O McNamara; Vittorio de Franciscis
Journal:  Methods Mol Biol       Date:  2009

Review 5.  Aptamers in immunotherapy.

Authors:  Claudia M Dollins; Smita Nair; Bruce A Sullenger
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

Review 6.  Aptahistochemistry in diagnostic pathology: technical scrutiny and feasibility.

Authors:  Bakhtiar A Bukari; Marimuthu Citartan; Ewe Seng Ch'ng; Mawethu P Bilibana; Timofey Rozhdestvensky; Thean-Hock Tang
Journal:  Histochem Cell Biol       Date:  2017-03-20       Impact factor: 4.304

Review 7.  Manipulating the in vivo immune response by targeted gene knockdown.

Authors:  Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2015-07-03       Impact factor: 7.486

Review 8.  Midkine and multiple sclerosis.

Authors:  Hideyuki Takeuchi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

9.  A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma.

Authors:  Nianxi Zhao; Hitesh G Bagaria; Michael S Wong; Youli Zu
Journal:  J Nanobiotechnology       Date:  2011-01-31       Impact factor: 10.435

10.  Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells.

Authors:  Peng Zhang; Nianxi Zhao; Zihua Zeng; Yongdong Feng; Ching-Hsuan Tung; Chung-Che Chang; Youli Zu
Journal:  Lab Invest       Date:  2009-10-12       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.